Does Rallies show Form 4 insider transactions for MGX?

Yes. Rallies tracks MGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is MGX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for MGX. It does not provide personalized investment advice.

MGX (Metagenomi Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Metagenomi Therapeutics, Inc. Common Stock (MGX) is a publicly traded Healthcare sector company. As of May 21, 2026, MGX trades at $1.34 with a market cap of $47.81M and a P/E ratio of -0.56. MGX moved +4.00% today. Year to date, MGX is -24.56%; over the trailing twelve months it is -24.12%. Its 52-week range spans $1.23 to $4.92. Analyst consensus is strong buy with an average price target of $8.00. Rallies surfaces MGX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading MGX stock inside the company?

Recent MGX insider activity includes Wapnick Pamela sold 1.58K, Wein Matthew sold 482, Irish Jian sold 1.61K, Thomas Brian C. sold 3.83K, and Wein Matthew sold 199. Rallies tracks insider transaction dates, shares, prices, and estimated values.

MGX Key Metrics

Key financial metrics for MGX
Metric	Value
Price	$1.34
Market Cap	$47.81M
P/E Ratio	-0.56
EPS	$-2.30
Dividend Yield	0.00%
52-Week High	$4.92
52-Week Low	$1.23
Volume	0
Avg Volume	0
Revenue (TTM)	$22.33M
Net Income	$-85.89M
Gross Margin	0.00%

Recent MGX Insider Trades

Wapnick Pamela sold 1.58K (~$2.53K) on Mar 5, 2026.
Wein Matthew sold 482 (~$771.2) on Mar 5, 2026.
Irish Jian sold 1.61K (~$2.57K) on Mar 5, 2026.
Thomas Brian C. sold 3.83K (~$6.79K) on Dec 5, 2025.
Wein Matthew sold 199 (~$352.608) on Dec 5, 2025.

Latest MGX News

Metagenomi Aims for Q4 2026 IND Filing with $140M Cash Runway — May 11, 2026
Metagenomi Posts Q4 $0.60 Loss and 54.8% Revenue Shortfall — Mar 5, 2026
Metagenomi Reports Curative FVIII Data, Plans 4Q 2026 IND Submission — Mar 5, 2026

MGX Analyst Consensus

3 analysts cover MGX: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $8.00.

Common questions about MGX

Who is trading MGX stock inside the company?: Recent MGX insider activity includes Wapnick Pamela sold 1.58K, Wein Matthew sold 482, Irish Jian sold 1.61K, Thomas Brian C. sold 3.83K, and Wein Matthew sold 199. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for MGX?: Yes. Rallies tracks MGX insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is MGX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for MGX. It does not provide personalized investment advice.